BRIM closes a $45.8 million rights issue early to accelerate its pipeline of regenerative peptides 2023-09-13 By admin
BRIM plans to launch a new funding round to accelerate late-stage clinical trial and initiate a new phase 2 trial for orphan drug BRM424 in the U.S 2023-05-09 By admin
BRM421, a new drug for treating Dry Eye Disease, receives approval to proceed to Phase 2 clinical trials in China 2023-04-18 By admin
BRIM Biotechnology announces first patient enrollment in pivotal Phase 3 clinical trial of BRM421 for Dry Eye Disease 2023-03-02 By admin
Novel regenerative peptide therapy for dry eye disease, BRM421, advances to Phase 3 clinical trials 2023-02-23 By admin
BRIM Biotechnology strengthens leadership team in preparation for transformational year ahead 2023-02-20 By admin
BRIM Biotechnology receives FDA Orphan Drug Designation for BRM424 to treat neurotrophic keratitis 2022-12-08 By admin
